EASTLAND JULIA MARIE — SEC Form 4 filings
SEC reporting owner CIK 1500189. 11 Form 4 filings on record with FilingPulse; latest filed 2026-05-18.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-01-09 to 2026-05-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 28,500 shares, $49,345 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 8,755 shares, $21,239 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: purchase of 28,500 shares @ $1.73 ($49,345) in Zentalis Pharmaceuticals, Inc., filed 2025-02-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | CEO & President, Director | 5 | 1 leg · 28,500 sh · $49,345 | 2 legs · 8,755 sh · $21,239 | 4 |
| Harpoon Therapeutics, Inc. (HARP) | President and CEO, Director | 2 | — | — | 5 |
| Lantheus Holdings, Inc. (LNTH) | Director | 3 | — | — | 5 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) | Director | 1 | — | — | 2 |
Form 4 filings — EASTLAND JULIA MARIE
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-18 | 4 | Lantheus Holdings, Inc. (LNTH) | Grant/award (A): 4,137 @ $0 | EDGAR |
| 2026-02-10 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 7,866 @ $2.43 · Sale (S): 889 @ $2.39 | EDGAR |
| 2026-01-09 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 775,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Lantheus Holdings, Inc. (LNTH) | Grant/award (A): 2,537 @ $0 · Grant/award (A): 4,543 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 59,388 @ $0 · Grant/award (A): 59,388 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Purchase (P): 28,500 @ $1.73 | EDGAR |
| 2024-12-03 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 3,028,800 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | Lantheus Holdings, Inc. (LNTH) | Grant/award (A): 1,345 @ $0 · Grant/award (A): 2,506 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Grant/award (A): 5,357 @ $0 · Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Harpoon Therapeutics, Inc. (HARP) | Grant/award (A): 31,250 @ $0 · Disposition to issuer (D): 269,381 · Disposition to issuer (D): 2,765 (derivative) · Disposition to issuer (D): 40,759 (derivative) | EDGAR |
| 2024-01-09 | 4 | Harpoon Therapeutics, Inc. (HARP) | Grant/award (A): 178,500 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1500189 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →